17:29 EDT C4 Therapeutics (CCCC) files to sell 4.87M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

BMO emphasized the significance of the attack-free rate and suggested that upcoming Phase II data could boost Intellia’s stock by 5-10%. Intellia Therapeutics, Inc. (NASDAQ:NTLA) also reported a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company ...

Also Read: Monte Rosa Therapeutics’ AI And Machine Learning ... Price Action: GLUE stock is up 30.1% at $6.35 during the premarket session at last check Monday.

Even though Intellia Therapeutics stock traded lower by 20% on the back of news of its release of a phase 1/2 study using NTLA-2002 for the treatment of patients with HAE, I believe this creates a ...

His company, Wilmette-based Monopar Therapeutics, announced yesterday ... according to the press release. Monopar's stock price on Nasdaq shot up on the news yesterday. The stock, which closed ...